Indoco Remedies Ltd.

NSE: INDOCO | BSE: 532612 | ISIN: INE873D01024 | Industry: Pharmaceuticals
| Weak Stock
198.2200 5.34 (2.77%)
NSE Apr 08, 2026 15:57 PM
Volume: 16,904
 

198.22
2.77%
ICICI Securities Limited
Q4 growth was led by strong growth in export markets (albeit on lower base) and lower staff, travel & promotional costs. The management expects 80-90 bps margin improvement in FY22 to ~19%. After going through rough patches in FY18-20, where Indoco faced headwinds on the domestic front (structural issues, pandemic) and exports front (regulatory setbacks), the situation is returning to normalcy. Indoco is expected to post strong FY22 topline growth as domestic sales normalise and grow amid opportunities arising out of post-Covid complications. Export formulations are also...
Indoco Remedies Ltd. is trading below its 50 day SMA of 200.7
More from Indoco Remedies Ltd.
Recommended